PDC-1421

Botanical

Partialsignal

Evidence outlook · lead readout

NCT02395978 · Major Depressive Disorder

The lead study reported mixed results: some prespecified endpoints were met and others were not. The tier describes the design; the rationale below says what the study found.

NCT02395978: The treatment phase was randomized, triple-blind, placebo-controlled, and included 60 participants across three groups, although the groups were small. Its primary clinical endpoint, change in MADRS score at week 6, was not statistically significant compared with placebo, so the findings provide limited evidence of benefit. Label revised to mixed on 2026-09-02: one dose arm shows a numerical advantage the sponsor reports as significant, the other shows none.

The registered primary (MADRS change at week 6 vs placebo, Part II) spans two dose arms: 2-capsule arm -13.19 vs placebo -9.2; 1-capsule arm -9.21 vs -9.2 (registry, ITT, ~20 per arm). The sponsor's 2019-06-05 release reports the high-dose arm met the prespecified primary; the registry results carry no p-values.

Also in development:Attention Deficit Hyperactivity Disorder · Phase 2

How the evidence outlook works ↗

All registered studies

Every ClinicalTrials.gov study of this drug's own program. Studies backing a featured trial above are marked Featured; the rest aren't individually graded. Filter by which indication a study was run for, then browse by phase.

Phase 2 (3)
Attention Deficit Hyperactivity Disorder
NCT05202327 · BioLite, Inc.
2022-04-07 – 2024-04-08 · Attention-Deficit Hyperactivity Disorder (ADHD)
What this study did
NCT02699086 · BioLite, Inc.
2019-12-01 – 2020-07-15 · Attention-Deficit Hyperactivity Disorder (ADHD)
What this study did
Major Depressive Disorder
Phase 1/2 (1)
Major Depressive Disorder
NCT03833206 · BioLite, Inc.
2027-01-15 – 2028-02-28 · Major Depressive Disorder
What this study did
Phase 1 (1)
Major Depressive Disorder

Competitive landscape

This drug's own stage for Attention Deficit Hyperactivity Disorder: Phase 2. Competitors below are sorted furthest-along first.

DrugStageModalityMechanismEvidence signalReported efficacygraded featured trials
PDC-1421: this drugPhase 2BotanicalPolygalae radix extract (active components: tenuifolin, polygalasaponins, etc.)not yet gradedNo reviewed efficacy summary in this indication
Centanafadine (Simtriyo)ApprovedSmall moleculeSerotonin/norepinephrine/dopamine transporterReliable signal
NCT05257265: ADHD-RS-5 change at week 6: -18.50 [0.93] centanafadine 328.8 mg vs -14.15 [0.93] placebo (p = .0006); 164.4 mg did not meet the primary endpoint
Viloxazine (Qelbree)ApprovedSmall moleculenorepinephrine transporterReliable signal
NCT04016779: Efficacy of SPN-812 on Symptoms of Attention-Deficit/Hyperactivity Disorder (ADHD) as Assessed by the Adult ADHD Investigator Symptom Rating Scale (AISRS) Total Score (Baseline and Week 6): Placebo -11.7 units on a scale (Standard Error 0.9) | SPN-812 -15.5 units on a scale (Standard Error 0.91)
NCT03247543: Efficacy of SPN-812 Assessed by Attention-Deficit/Hyperactivity Disorder Rating Scale, 5th Edition (ADHD-RS-5) (Baseline and Week 8 (End of Study)): Placebo -11.7 units on a scale (Standard Error 1.48) | 200mg SPN-812 -17.6 units on a scale (Standard Error 1.43) | 400mg SPN-812 -17.5 units on a scale (Standard Error 1.52)
Solriamfetol (Sunosi)Phase 3Small moleculeDopamine/norepinephrine transporternot yet gradedNo reviewed efficacy summary in this indication
Lysergide Tartrate (LSD) (DT120)Phase 2Small molecule5-HT2A receptornot yet gradedNo reviewed efficacy summary in this indication

Upcoming events

(1 total)

Estimated primary-completion dates from ClinicalTrials.gov. These are registry estimates, never confirmed readout dates; they can move as trials progress.

Follow PDC-1421 to get an email as a readout nears, when a date moves, or when a study changes status. Needs a free account.

Add these readouts to your calendar: Apple or Outlook · Google Calendar · .ics link. The calendar updates when a registry date moves.

2028 (1)
February 2028 (1)
Phase 1/2Major Depressive DisorderNot yet recruiting
Est. primary completion 2028-02-28 · NCT03833206 · CT.gov ↗
What to watch

See the full readout calendar ↗